Methemoglobinemia secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Methemoglobinemia}} | {{Methemoglobinemia}} | ||
{{CMG}}; {{AE}}{{ | {{CMG}}; {{AE}}{{AKS}} | ||
==Overview== | ==Overview== | ||
Line 7: | Line 7: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Secondary prevention consists of avoiding oxidizing agents in people with diagnosed G6PD deficiency or known congenital deficiency of the reductase enzyme. | Secondary prevention consists of avoiding [[oxidizing agents]] in people with diagnosed [[G6PD deficiency]] or known [[congenital]] deficiency of the [[reductase enzyme]]. | ||
==References== | ==References== |
Latest revision as of 20:34, 21 June 2018
Methemoglobinemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Methemoglobinemia secondary prevention On the Web |
American Roentgen Ray Society Images of Methemoglobinemia secondary prevention |
Risk calculators and risk factors for Methemoglobinemia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aksiniya Stevasarova, M.D.
Overview
Secondary Prevention
Secondary prevention consists of avoiding oxidizing agents in people with diagnosed G6PD deficiency or known congenital deficiency of the reductase enzyme.